HLB Genex
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
HLB Genex develops and produces custom enzymes and bio-healthcare ingredients, for example, a catalase enzyme used to break down hydrogen peroxide in semiconductor and textile water-treatment processes, and a lactase enzyme used to make a probiotic ingredient found in breast milk.
Its products reach customers across environmental, food, and cosmetics industries, as well as health-supplement and pharmaceutical supply chains. Listed on KOSDAQ, Korea's tech and small-cap board, the company operates across three main lines: industrial specialty enzymes, bio-healthcare materials, and microbiome-enzyme product development.
Summary is AI-generated and may contain errors · figures from DART filings
HLB Genex has a subsidiary, HLB Neurotrove, founded as a KAIST faculty startup, which conducts early-stage drug research targeting neurological diseases such as dystonia and Parkinson's disease.
HLB Genex in five facts
What does HLB Genex do?
HLB Genex develops and produces custom enzymes and bio-healthcare ingredients, for example, a catalase enzyme used to break down hydrogen peroxide in semiconductor and textile water-treatment processes, and a lactase enzyme used to make a probiotic ingredient found in breast milk.
Where is HLB Genex listed and in which sector?
HLB Genex (Korean name: HLB제넥스) trades under KRX code 187420 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is HLB Genex?
Its market capitalisation was US$58.7M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were HLB Genex's latest annual revenue and operating profit?
For fiscal year 2025, HLB Genex reported revenue of US$32.7M, operating profit of US$910K and net income of US$17.3M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 22.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Oct 15
- Investor relations (IR) meetingOct 12
- Report on large shareholdings (5% rule) (standard)Sep 17
- Report on securities held by executives/major shareholdersSep 17
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Sep 14
- Conversion price adjustmentSep 14
- Early redemption of convertible bonds (incl. overseas CBs)
HLB Genex Co., Ltd. acquired US$13.8M face value of its Series 5 convertible bonds (issued 2024-12-12, maturing 2027-12-12, conversion price US$1.57 per share, as finally adjusted on 2026-06-12) on 2026-08-14 for US$14.1M (principal plus interest) using cash on hand by separate agreement with the bondholder, leaving US$18.4M of the bonds outstanding; future treatment is to be determined by the board.
Capital raise · Aug 14 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Jun 12
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Apr 6
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
HLB Genex reported consolidated results for FY2025: revenue of US$29.5M (+22.4% year on year), operating profit of US$820K (from a loss a year earlier) and net income of US$15.6M (from a loss a year earlier).
Earnings · Mar 13